Capecitabine monotherapy in advanced breast cancer resistant to anthracycline and taxane: A meta-analysis

被引:4
作者
Jiang, Zhansheng [1 ]
Yang, Yanfang [2 ]
Li, Ling [1 ]
Yue, Zhensong [1 ]
Lan, Lan [1 ]
Pan, Zhanyu [1 ]
机构
[1] Tianjin Med Univ, Key Lab Breast Canc Prevent & Therapy, Canc Inst & Hosp,Tianjin Key Lab Canc Prevent & T, Minist Educ,Dept Integrat Oncol,Natl Clin Res Ctr, Tianjin, Peoples R China
[2] Tianjin Med Univ, Key Lab Breast Canc Prevent & Therapy, Canc Inst & Hosp,Tianjin Key Lab Canc Prevent & T, Dept Breast Canc 2,Minist Educ,Natl Clin Res Ctr, Tianjin, Peoples R China
关键词
Advanced breast cancer; capecitabine; chemotherapy; meta-analysis; resistance; PHASE-III TRIAL; IXABEPILONE PLUS CAPECITABINE; OPEN-LABEL; VINORELBINE MONOTHERAPY; 2ND-LINE TREATMENT; BEVACIZUMAB; CHEMOTHERAPY; MULTICENTER; COMBINATION; SUNITINIB;
D O I
10.4103/0973-1482.187384
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Capecitabine monotherapy is usually used for advanced breast cancer (ABC) resistant to anthracycline and taxane, but there are still many other options too. Our meta-analysis assessed whether capecitabine monotherapy was superior or noninferior to the other regimens in ABC pretreated with anthracycline and taxane. Materials and Methods: PubMed databases and abstracts from the proceedings of American Society of Clinical Oncology and San Antonio Breast Cancer Symposium were searched for randomized controlled trials that compared capecitabine monotherapy with other regimens for ABC progression after anthracycline- and taxane-treatment. Hazard ratios (HRs) were used for progression-free survival (PFS) and overall survival (OS). Risk ratios (RRs) were used for overall response rate (ORR) and Grade 3u4 drug-related adverse events. All statistical analyses were conducted with RevMan 5.3 software, and statistical significance was defined as P < 0.05. Results: In total, 4671 patients from eight trials were included. Target therapy as treatment group was involved in four trials, and the other four trials were merely chemotherapy in treatment group. Our study indicated that capecitabine monotherapy was not superior but also noninferior to the other regimens in ORR (RR = 1.3295% confidence interval [CI] 0.98u1.77, P = 0.07), PFS (HR = 1.03, 95% CI 0.85u1.25, P = 0.76), and OS (HR = 0.96, 95% CI 0.88u1.05, P = 0.40). Subgroup analysis showed that both the other chemotherapy regimens and target drugs failed to improve efficacy compared with capecitabine monotherapy, and target drugs could shorten PFS (HR = 1.22, 95% CI 1.06u1.39, P = 0.004). Incidences of Grade 3u4 hematology toxicity in other regimens group significantly increased compared with capecitabine monotherapy. Conclusions: Our meta-analysis demonstrated that capecitabine monotherapy could be the first choice for ABC pretreated with anthracycline and taxane due to its efficacy and low toxicity.
引用
收藏
页码:S957 / S963
页数:7
相关论文
共 28 条
[1]   Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer [J].
Barrios, Carlos H. ;
Liu, Mei-Ching ;
Lee, Soo Chin ;
Vanlemmens, Laurence ;
Ferrero, Jean-Marc ;
Tabei, Toshio ;
Pivot, Xavier ;
Iwata, Hiroji ;
Aogi, Kenjiro ;
Lugo-Quintana, Roberto ;
Harbeck, Nadia ;
Brickman, Marla J. ;
Zhang, Ke ;
Kern, Kenneth A. ;
Martin, Miguel .
BREAST CANCER RESEARCH AND TREATMENT, 2010, 121 (01) :121-131
[2]   Incidence and Patterns of Distant Metastases for Patients With Early-Stage Breast Cancer After Breast Conservation Treatment [J].
Berman, Abigail T. ;
Thukral, Arpi D. ;
Hwang, Wei-Ting ;
Solin, Lawrence J. ;
Vapiwala, Neha .
CLINICAL BREAST CANCER, 2013, 13 (02) :88-94
[3]   RIBBON-2: A Randomized, Double-Blind, Placebo-Controlled, Phase III Trial Evaluating the Efficacy and Safety of Bevacizumab in Combination With Chemotherapy for Second-Line Treatment of Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer [J].
Brufsky, Adam M. ;
Hurvitz, Sara ;
Perez, Edith ;
Swamy, Raji ;
Valero, Vicente ;
O'Neill, Vincent ;
Rugo, Hope S. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (32) :4286-4293
[4]   Phase II Clinical Trial of Ixabepilone in Metastatic Cervical Carcinoma [J].
Burotto, Mauricio ;
Edgerly, Maureen ;
Poruchynsky, Marianne ;
Velarde, Margarita ;
Wilkerson, Julia ;
Kotz, Herb ;
Bates, Susan ;
Balasubramaniam, Sanjeeve ;
Fojo, Tito .
ONCOLOGIST, 2015, 20 (07) :725-726
[5]  
Camidge D Ross, 2008, Anticancer Drugs, V19, P77
[6]   ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2) [J].
Cardoso, F. ;
Costa, A. ;
Norton, L. ;
Senkus, E. ;
Aapro, M. ;
Andre, F. ;
Barrios, C. H. ;
Bergh, J. ;
Biganzoli, L. ;
Blackwell, K. L. ;
Cardoso, M. J. ;
Cufer, T. ;
El Saghir, N. ;
Fallowfield, L. ;
Fenech, D. ;
Francis, P. ;
Gelmon, K. ;
Giordano, S. H. ;
Gligorov, J. ;
Goldhirsch, A. ;
Harbeck, N. ;
Houssami, N. ;
Hudis, C. ;
Kaufman, B. ;
Krop, I. ;
Kyriakides, S. ;
Lin, U. N. ;
Mayer, M. ;
Merjaver, S. D. ;
Nordstrom, E. B. ;
Pagani, O. ;
Partridge, A. ;
Penault-Llorca, F. ;
Piccart, M. J. ;
Rugo, H. ;
Sledge, G. ;
Thomssen, C. ;
van't Veer, L. ;
Vorobiof, D. ;
Vrieling, C. ;
West, N. ;
Xu, B. ;
Winer, E. .
BREAST, 2014, 23 (05) :489-502
[7]   Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy [J].
Clemons, Mark ;
Joy, Anil A. ;
Abdulnabi, Radhi ;
Kotliar, Mauricio ;
Lynch, Jodi ;
Jordaan, Johan P. ;
Iscoe, Neill ;
Gelmon, Karen .
BREAST CANCER RESEARCH AND TREATMENT, 2010, 124 (01) :177-186
[8]   Eribulin monotherapy versus treatment of physician's choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study [J].
Cortes, Javier ;
O'Shaughnessy, Joyce ;
Loesch, David ;
Blum, Joanne L. ;
Vahdat, Linda T. ;
Petrakova, Katarina ;
Chollet, Philippe ;
Manikas, Alexey ;
Dieras, Veronique ;
Delozier, Thierry ;
Vladimirov, Vladimir ;
Cardoso, Fatima ;
Koh, Han ;
Bougnoux, Philippe ;
Dutcus, Corina E. ;
Seegobin, Seth ;
Mir, Denis ;
Meneses, Nicole ;
Wanders, Jantien ;
Twelves, Chris .
LANCET, 2011, 377 (9769) :914-923
[9]   Phase III Trial of Sunitinib in Combination With Capecitabine Versus Capecitabine Monotherapy for the Treatment of Patients With Pretreated Metastatic Breast Cancer [J].
Crown, John P. ;
Dieras, Veronique ;
Staroslawska, Elzbieta ;
Yardley, Denise A. ;
Bachelot, Thomas ;
Davidson, Neville ;
Wildiers, Hans ;
Fasching, Peter A. ;
Capitain, Olivier ;
Ramos, Manuel ;
Greil, Richard ;
Cognetti, Francesco ;
Fountzilas, George ;
Blasinska-Morawiec, Maria ;
Liedtke, Cornelia ;
Kreienberg, Rolf ;
Miller, Wilson H., Jr. ;
Tassell, Vanessa ;
Huang, Xin ;
Paolini, Jolanda ;
Kern, Kenneth A. ;
Romieu, Gilles .
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (23) :2870-+
[10]   Multicentre, phase II study evaluating capecitabine monotherapy in patients with anthracycline- and taxane-pretreated metastatic breast cancer [J].
Fumoleau, P ;
Largillier, R ;
Clippe, C ;
Dièras, V ;
Orfeuvre, H ;
Lesimple, T ;
Culine, S ;
Audhuy, B ;
Serin, D ;
Curé, H ;
Vuillemin, E ;
Morère, JF ;
Montestruc, F ;
Mouri, Z ;
Namer, M .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (04) :536-542